MRNA

#578
Moderna, Inc. Common Stock
52.60 USD
+3.79%
セクター: ヘルスケア
ベース: USD
利益通貨: USD
日中レンジ
52.35
52.69
1年のレンジ
22.29
59.55
1日の変化
+3.79%
月次変化
-1.50%
6か月変化
+98.19%
1年の変化
+96.12%
以前の終値
50.68
始値
52.57
Bid
Ask
安値
52.35
High
52.69
ボリューム
470
チャート全体を表示

Financials

概要 明細書 統計
期次 年次
  • Market Capitalization 20.77 B
  • Employee 4 700
  • Founded N/A
  • CEO Stéphane Bancel
  • Website www.modernatx.com
  • Headquarter Delaware, United States
  • FIGI BBG003PHHZT1
  • Industry Technology
総売上高
当期純利益
1株当たり基本利益（基本EPS）
有利子負債合計
フリーキャッシュフロー
現金および現金同等物
株価収益率
-4.06
売上高対価格比率
5.9

Moderna Inc

Moderna, Inc. is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics, primarily mRNA vaccines. These vaccines use a copy of a molecule called messenger RNA to carry instructions for proteins to produce an immune response. The company's name is derived from the terms "modified", "RNA", and "modern". The company's commercial products are the Moderna COVID-19 vaccine, marketed as Spikevax and a respiratory syncytial virus vaccine, marketed as Mresvia. The company has 44 treatment and vaccine candidates, of which 37 have entered clinical trials. Candidates include possible vaccines for influenza, HIV, Epstein–Barr virus, the Nipah virus, chikungunya, human metapneumovirus, varicella zoster virus, as well as a cytomegalovirus vaccine, a Zika virus vaccine funded by the Biomedical Advanced Research and Development Authority, and three cancer vaccines.

ニュース